Allergo-immunologie. 1. Nouveaux concepts de traitement du lupus erythemateux dissemine. [New concepts for the therapy of systemic lupus erythematosus]

Détails

ID Serval
serval:BIB_0EEC87173254
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Allergo-immunologie. 1. Nouveaux concepts de traitement du lupus erythemateux dissemine. [New concepts for the therapy of systemic lupus erythematosus]
Périodique
Revue Médicale Suisse
Auteur(s)
Spertini F.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
2007
Volume
3
Numéro
94
Pages
98-102
Notes
English Abstract Journal Article Review
Résumé
Immediate, short- and long-term adverse events of classical immunosuppressor drugs strongly stimulate novel, but less toxic approaches. Combined or sequential use of cyclophosphamide, mycophenolate mofetil and/ or azathioprine should improve clinical tolerance and avoid severe adverse events (infections, infertility, amenorrhea), regularly associated to long term therapies with classical immunosuppressive schemes. Among novel developments based on biologicals, the anti-CD20 monoclonal antibody rituximab (anti-B cells) appears encouraging in open studies, in association or not with cyclophosphamide, and is generally well tolerated. Further information is expected from the inhibitor of T cell/B cell co-stimulation CTLA4-Ig, or from strategies aiming to inhibit key cytokines in SLE pathogenesis such as interferon-alpha, IL-1 or IL-6.
Mots-clé
B-Lymphocytes/drug effects Humans Immunosuppressive Agents/*therapeutic use Lupus Erythematosus, Systemic/*drug therapy
Pubmed
Création de la notice
25/01/2008 15:20
Dernière modification de la notice
20/08/2019 12:35
Données d'usage